SCM
PNT

Silverarc Capital Management’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

Silverarc Capital Management’s Portfolio PNT Stock Details PNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-93,700
Closed -$625K – 95
2023
Q3 		$625K Hold
93,700
– – 0.19% 67
2023
Q2 		$849K Sell
93,700
-104,777
-53% -$924K 0.26% 63
2023
Q1 		$1.44M Sell
198,477
-202,335
-50% -$1.5M 0.6% 50
2022
Q4 		$2.92M Buy
400,812
+100,812
+34% +$748K 0.84% 41
2022
Q3 		$2.32M Buy
+300,000
New +$2.55M 0.78% 42
2022
Q2 		– Sell
-204,679
Closed -$1.63K – 85
2022
Q1 		$1.63K Buy
204,679
+217
+0.1% +$1.38K 0.67% 37
2021
Q4 		$1.15M Buy
204,462
+132,733
+185% +$996K 0.46% 58
2021
Q3 		$552K Buy
+71,729
New +$654K 0.31% 64
2021
Q2 		– Sell
-40,000
Closed -$420K – 120
2021
Q1 		$420K Buy
40,000
+991
+3% +$13.4K 0.23% 78
2020
Q4 		$543K Buy
+39,009
New +$542K 0.32% 71

Other funds holding PNT

BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Silverarc Capital Management's PNT Position: Q4 2023 in Review

Silverarc Capital Management sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q4 2023, closing a stake of 93,700 shares — an estimated $625K sold.

Silverarc Capital Management first reported a position in PNT in Q4 2020 and held it in 10 quarters. The position peaked at $2.92M in Q4 2022. 1 fund tracked by Wall St. Rank holds PNT as of Q4 2023.

  • Silverarc Capital Management reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Silverarc Capital Management sold 93,700 POINT Biopharma Global Inc. Common Stock shares in Q4 2023, an estimated $625K.
  • Silverarc Capital Management first reported a position in POINT Biopharma Global Inc. Common Stock in Q4 2020 and held it in 10 quarters.
  • Silverarc Capital Management's POINT Biopharma Global Inc. Common Stock position peaked at $2.92M in Q4 2022.
  • 1 fund tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q4 2023.

Based on Silverarc Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.